Interferon gamma-1b - Biologic Drug Details

Summary for interferon gamma-1b

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for interferon gamma-1b

Recent Clinical Trials for interferon gamma-1b

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE1
City of Hope Medical Center	PHASE1
Ferring Pharmaceuticals	PHASE2

See all interferon gamma-1b clinical trials

Pharmacology for interferon gamma-1b

Established Pharmacologic Class	Interferon gamma
Chemical Structure	Interferon-gamma

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for interferon gamma-1b Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for interferon gamma-1b Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for interferon gamma-1b Derived from Patent Text Search

No patents found based on company disclosures

Interferon gamma-1b Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics and Financial Trajectory for Interferon Gamma-1b

Interferon gamma-1b (brand name Actimmune) is a biologic indicated primarily for chronic granulomatous disease (CGD) and severe malignant osteopetrosis. The drug’s market presence is shaped by disease prevalence, regulatory status, competitive landscape, and reimbursement policies.

Market Overview

Indications and Prevalence

• Chronic Granulomatous Disease (CGD): An ultra-rare genetic disorder affecting approximately 1 in 200,000 to 250,000 live births in the U.S. and Europe.
• Osteopetrosis: Particularly severe forms are rare, affecting about 1 in 250,000 individuals, with limited treatment options.

Market Size

• Estimated global sales: approximately $100 million in 2022 (per IQVIA estimates).
• U.S. accounted for roughly 60-70% of sales, driven by clinical adoption.
• The overall market growth rate remains low, given rare disease status and limited patient populations.

Key Market Drivers

1. Orphan Drug Designation: Extends market exclusivity; Actimmune received FDA orphan designation, facilitating market maintenance.
2. Expansion of Indications: Trials to expand use to other indications such as certain infections or immune deficiencies have been limited.
3. Pricing and Reimbursement: Average wholesale prices (AWP) in the U.S. range between $80,000–$100,000 annually per patient; reimbursement policies vary across regions.
4. Physician and Patient Adoption: Limited by disease rarity, but sustained by lack of alternative therapies.

Competitive Landscape

• No direct biologic competitors exist for the primary indications.
• Small molecule immunotherapies: Do not directly compete but impact market perception.
• Off-label use and experimental therapies could influence future dynamics but currently have limited traction.

Regulatory and R&D Landscape

• FDA status: Approved since 1993 for CGD, with continuous approvals since.
• Clinical Trials: Limited ongoing studies to expand indications or improve delivery; recent trials focused on safety and dosage refinement.
• Regulatory barriers: Challenges persist with off-label use restrictions and the need for ongoing clinical validation.

Financial Trajectory

Year	Estimated Global Sales	Key Factors Influencing Revenue	Comments
2022	~$100 million	Stable use in CGD and osteopetrosis, patent protections in place	Market mature, growth plateauing unless new indications emerge
2023	~$105–115 million	Slight growth driven by increased awareness, inflation, and potential off-label use	Limited by small patient population and competition for R&D funding
2024–2026	$110–130 million	Possible new clinical data, reimbursement optimization, and regional expansion	Growth potential hinges on indication expansion and market access strategies

Financial Risks and Opportunities

• Pricing pressures: Payers demand discounts or value-based agreements, affecting margins.
• R&D investments: Limited pipeline reduces potential future revenues absent new indications.
• Market exclusivity: Patent expiration expected around 2024–2027 (pending patent term adjustments), risking generic or biosimilar entry.
• Patient access programs: Can mitigate reimbursement barriers but impact revenue timing and volume.

Conclusion

Interferon gamma-1b remains a niche biologic with stable, albeit limited, revenue. Its growth potential relies heavily on expanding indications, maintaining regulatory exclusivity, and navigating reimbursement policies. The lack of competition supports steady revenue, but the small patient base constrains significant growth.

---

Key Takeaways

• The global market for interferon gamma-1b stood at around $100 million in 2022.
• Growth is slow, driven by rare disease prevalence and lack of new indications.
• Revenue stability depends on patent protection and regional reimbursement success.
• Competition remains limited, primarily from off-label use and future biosimilar entries.
• Expansion efforts are minimal, with future growth tied to clinical trials and regulatory pathways.

---

FAQs

1. What are the main factors limiting growth for interferon gamma-1b?
The limited size of target patient populations, absence of new approved indications, and potential patent expirations restrict expansion.

2. How do reimbursement policies impact sales?
Reimbursement varies by region, with some payers demanding discounts or value-based agreements, affecting net revenues.

3. Are biosimilars a significant threat?
Patent expiry could open the market to biosimilars post-2024, potentially lowering prices and market share.

4. What is the potential for expanding indications?
Research into additional infections or immune disorders exists but has yet to produce substantial clinical or regulatory progress.

5. How does the competitive landscape influence market stability?
The lack of direct competitors ensures stable revenue but also limits growth opportunities; off-label use and experiments could alter this.

---

Sources:
[1] IQVIA, 2022 Sales Data
[2] U.S. FDA database
[3] GlobalData Pharma Intelligence
[4] Orphan Drug Designation records